MilanaPharm Announces Publication of Wound Pain Study
OPELIKA, AL — MilanaPharm, a specialty pharmaceutical company focused on the development of innovative, non-opioid pharmaceutical solutions for wound management and pain, announced today that a new study covering treatment of wound pain has been published.
The study, “Treatment of Pain In Wounds With A Topical Long Acting Lidocaine Gel, was authored by T. Treadwell, et al and published in Chronic Wound Care Management and Research. [Vol 2019:6 117-121]
According to the study’s abstract, “The treatment of patients with chronic wounds and pain can be frustrating and filled with potential for medication abuse and addiction.”
In an attempt to improve the management of this chronic wound pain, a gel containing 4% lidocaine in patented TRI-726 matrix (lidocaine gel) was evaluated in 33 patients with various types of chronic painful wounds. In this weeklong study, the new lidocaine gel was applied once on day 0 and patients recorded their perceived pain level for the next 7 days. Mean reported pain scores and pain intensity difference (PID) were statistically significantly lower on days 1-4 compared to day 0 and days 5-7. This new lidocaine gel was effective in reducing the pain in the majority of patients for multiple days after one application.
The data from this study supports further studies to determine if long-term use will reduce the amount of pain medication prescribed in this group of patients.
About MilanaPharm
MilanaPharm is a specialty pharmaceutical company working on non-opioid solutions for wound management and pain relief. Their proprietary drug delivery platform, TRI-726, is capable of delivering a large number of actives over several hours to several days. The platform imparts in-situ gelation, sustained-erosion and bio-resorption, and adhesion. MilanaPharm is based in Central Alabama. For more information visit www.milanapharm.com.
Media Contact
Shannon Leighty
sleighty@milanapharm.com
417-861-1148
Investor Contact
Jim Harwick
jharwick@milanapharm.com
866-562-8042